Tachibana Mitsuo, Dhar Dipok Kumar, Kinugasa Shoichi, Yoshimura Hiroshi, Fujii Toshiyuki, Shibakita Muneaki, Ohno Satoshi, Ueda Shuhei, Kohno Hitoshi, Nagasue Naofumi
Second Department of Surgery, Shimane Medical University, Enya-cho 89-1, Izumo 693-8501, Japan.
Langenbecks Arch Surg. 2002 Jun;387(2):77-83. doi: 10.1007/s00423-002-0290-1. Epub 2002 Apr 30.
Esophageal cancer is one of the most malignant tumors, with a dismal prognosis in spite of recent advances in early diagnosis and extended lymphadenectomy. These patients need to be stratified according to prognostic variables for precise identification of high-risk group.
Seventy-six patients with esophageal carcinoma were uniformly treated with curative intent between 1980 and 1992 with at least 6 years follow-up. Results and prognostic factors of long-term survival were analyzed by univariate and multivariate analyses.
Thirty patients (39.5%) survived 6 years, and the remaining 46 patients died within 6 years: recurrent esophageal cancer in 27 and causes unrelated to esophageal cancer in 19. The 1-, 2-, 3-, and 6-year overall survival rates in all 76 patients were 77.6%, 57.9%, 53.9%, and 39.5%, respectively. The factors influencing survival rate verified by univariate analysis were Borrmann classification (0, 1 vs. 2, 3), size of tumor (< or =3.0 vs. >3.0 cm), depth of invasion (T1, 2 vs. T3, 4), pN category (pN0 vs. pN1), number of lymph node metastasis (< or =4vs. >4), metastatic lymph node ratio (< or =0.1 vs. >0.1), time of operation (< or =480 vs. >480 min), and amount of perioperative blood transfusion given (< or =2 vs. >2 U). Among the significant variables independent prognostic factors for survival determined by multivariate analysis were metastatic lymph node ratio and amount of blood transfusion.
A significant number of patients can thus apparently be cured of esophageal carcinoma by extensive resection. Patients with many metastatic lymph nodes and much blood transfusion, on the other hand, should receive appropriate treatment against such esophageal carcinoma.
食管癌是最恶性的肿瘤之一,尽管早期诊断和扩大淋巴结清扫术取得了进展,但其预后仍不容乐观。这些患者需要根据预后变量进行分层,以精确识别高危组。
1980年至1992年间,76例食管癌患者均接受了根治性治疗,随访至少6年。通过单因素和多因素分析分析长期生存的结果和预后因素。
30例患者(39.5%)存活6年,其余46例患者在6年内死亡:27例为复发性食管癌,19例为与食管癌无关的原因。76例患者的1年、2年、3年和6年总生存率分别为77.6%、57.9%、53.9%和39.5%。单因素分析验证的影响生存率的因素有Borrmann分型(0、1与2、3)、肿瘤大小(≤3.0与>3.0 cm)、浸润深度(T1、2与T3、4)、pN分类(pN0与pN1)、淋巴结转移数(≤4与>4)、转移淋巴结比例(≤0.1与>0.1)、手术时间(≤480与>480分钟)和围手术期输血量(≤2与>2 U)。多因素分析确定的生存独立预后因素的显著变量为转移淋巴结比例和输血量。
大量患者通过广泛切除显然可以治愈食管癌。另一方面,有许多转移淋巴结和大量输血的患者应接受针对此类食管癌的适当治疗。